Pancreatic cancer patients continue to thrive after early trial of mRNA-based vaccine

<p>Almost half of the participants in an early trial of an mRNA-based vaccine to fight pancreatic cancer were alive and well up to six years after treatment, according to new research. CNN's Brianna Keilar speaks with Dr. Vinod Balachandran, director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, who led the study. </p>